



**PB 65 of 2024**

# **National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 3) 2024**

---

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following Determination.

Dated 4 June 2024

Nikolai Tsyganov  
Assistant Secretary  
Pricing and PBS Policy Branch  
Technology Assessment and Access Division  
Department of Health and Aged Care



---

# Contents

1 Name .....	1
2 Commencement.....	1
3 Authority .....	1
4 Schedules.....	1
<b>Schedule 1—Amendments—General</b>	<b>2</b>
<i>National Health (Floor Price for Certain Brands of Pharmaceutical Items)</i> <i>Determination 2023</i>	2
<b>Schedule 2—Amendments—Additional designated brands effective from 1 December 2024</b>	<b>3</b>
<i>National Health (Floor Price for Certain Brands of Pharmaceutical Items)</i> <i>Determination 2023</i>	3



---

## 1 Name

- (1) This instrument is the *National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 3) 2024*.
- (2) This instrument may also be cited as PB 65 of 2024.

## 2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	The day after this instrument is registered.	18 July 2024
2. Schedule 1	The day after this instrument is registered.	18 July 2024
3. Schedule 2	1 December 2024.	1 December 2024

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

## 3 Authority

This instrument is made under subsection 99ADHC(2) of the *National Health Act 1953*.

## 4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

---

## Schedule 1—Amendments—General

### *National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023*

#### 1 Section 5 (table)

Omit:

K.Quik

Triglycerides,  
medium chain

Oral liquid 225 mL, 15 (K.Quik)

Oral

---

## Schedule 2—Amendments—Additional designated brands effective from 1 December 2024

### *National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023*

#### **1 Section 5 (after table item dealing with the brand Flagyl of the drug Metronidazole in the form Suppositories 500 mg, 10)**

Insert:

MS-2 Step	Mifepristone and misoprostol	Pack containing 1 tablet mifepristone 200 mg and 4 tablets misoprostol 200 micrograms	Oral
-----------	------------------------------	---	------

#### **2 Section 5 (after table item dealing with the brand Teglutik of the drug Riluzole in the form Oral suspension 50 mg per 10 mL, 300 mL)**

Insert:

Salbutamol Cipla	Salbutamol	Nebuliser solution 2.5 mg (as sulfate) in 2.5 ml single dose units, 30	Inhalation
Salbutamol Cipla	Salbutamol	Nebuliser solution 5 mg (as sulfate) in 2.5 ml single dose units, 30	Inhalation

#### **3 Section 5 (after table item dealing with the brand Lipistart of the drug Triglycerides - medium chain, formula in the form Oral powder 400 g (Lipistart))**

Insert:

Valine 1000	Valine with carbohydrate	Sachets of oral powder 4 g containing 1 g valine, 30 (Valine 1000)	Oral
Valine 50	Valine with carbohydrate	Sachets of oral powder 4 g containing 50 mg valine, 30 (Valine 50)	Oral